Page 39 - Nsclc News Today

The FDA has granted an orphan drug designation to rucosopasem manganese for the treatment of patients with pancreatic cancer.

The combination of osimertinib and platinum-based chemotherapy led to a statistically significant and clinically meaningful improvement in progression-free survival compared with osimertinib alone in patients with locally advanced or metastatic non–small cell lung cancer harboring EGFR mutations.

Osimertinib plus chemotherapy showed a statistically significant improvement in progression-free survival (PFS) vs osimertinib alone in patients with epidermal growth factor receptor–mutated (EGFRm) advanced non–small cell lung cancer (NSCLC)

In addition to improving overall survival, the PD-1 inhibitor cemiplimab shows improvements in patient-reported quality-of-life measures.

It is important to have a multidisciplinary approach in the treatment of patients with small cell lung cancer, according to Jason Porter, MD, medical oncologist and hematologist, West Cancer Center and Research Institute, Memphis, Tennessee. This team approach allows for early intervention with signs of relapse or progression.

MyJournals.org - Science - The combination therapy of isomucronulatol 7-O-beta-glucoside (IMG) and CEP-9722 targeting ferroptosis-related biomarkers in non-small cell lung cancer (NSCLC) (BMC Pulmonary Medicine)

Devika Das, MD, MSHQS, discusses the activity and tolerability of lurbinectedin and topotecan as second-line regimens in extensive-stage small cell lung cancer.

Luis G. Paz-Ares, MD, PhD, discusses the importance of next-generation sequencing and highlights current challenges with NGS for patients with non–small cell lung cancer.

An analysis of the EMPOWER‐Lung 3 trial found that the addition of cemiplimab to platinum chemotherapy for non­–small cell lung cancer (NSCLC) was associated with improved patient quality of life (QOL) vs chemotherapy alone.

Looking at real-world data from 2011-2021, researchers identified a large increase of biomarker testing for patients with early-stage non–small cell lung cancer, which indicates a continuing trend toward personalized treatment.